Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Genuv Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner and 1 distinct art unit, which limits the scope of active review to a single point of contact. Such a concentrated profile suggests that the company's current legal activity at the office is focused on a specific technical advancement or a single patent application.
The busiest examiner for this portfolio is KIM, SEONG JONG, who holds 1 busiest examiner pending office action. This single examiner is responsible for all of the company's current active prosecution matters, which can streamline the communication and strategy for the practitioner. Because there is only 1 distinct examiner and 1 pending office action, there is no need to coordinate across different art units or manage multiple reviewer personalities.
Within the Biotechnology & Pharmaceuticals field, the involvement of only 1 distinct art unit indicates a narrow technical scope for the current filing. The practitioner can focus all resources on addressing the specific requirements and feedback from KIM, SEONG JONG. This singular focus on 1 busiest examiner pending office action allows for a dedicated and efficient approach to the company's current patent objectives at the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943857 | STABLE LIQUID PHARMACEUTICAL FORMULATION | KIM, SEONG JONG | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943857 | STABLE LIQUID PHARMACEUTICAL FORMULATION | KIM, SEONG JONG | 1621 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenuv Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Seong Jong Kim has the most, with 1 of Genuv Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
